Brichkov Igor, Keller Steven M
Department of Cardiothoracic Surgery, Division of Thoracic Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, 3400 Bainbridge Avenue - 5th floor, Bronx, NY 10467, USA.
Thorac Surg Clin. 2008 Nov;18(4):381-91. doi: 10.1016/j.thorsurg.2008.08.003.
Staging of the mediastinum is an integral component of the operative treatment of NSCLC. Systematic sampling and systematic lymph node dissection provide similar and accurate staging information. Systematic lymph node dissection is more likely to identify multiple levels of N2 disease, however, and may be associated with improved survival. During surgery for a right lung cancer, at least mediastinal lymph node levels 4 should be sampled or dissected. When removing a left lung cancer, at least nodal levels 5 and 7 should be assessed. Although every effort should be made to identify N2 disease before surgery, if intraoperative metastases to mediastinal lymph nodes are discovered, the planned operation should proceed. Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of PORT remains uncertain.
纵隔分期是NSCLC手术治疗的一个重要组成部分。系统采样和系统性淋巴结清扫可提供相似且准确的分期信息。然而,系统性淋巴结清扫更有可能识别出多个N2期疾病水平,并且可能与生存率提高相关。在右肺癌手术期间,至少应采样或清扫纵隔淋巴结4组。在切除左肺癌时,至少应评估5组和7组淋巴结。尽管应尽一切努力在手术前识别N2期疾病,但如果术中发现纵隔淋巴结转移,仍应按计划进行手术。基于顺铂的辅助化疗在N2期疾病切除后具有适度但已证实的生存益处。术后放疗(PORT)的作用仍不确定。